E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic Graft Versus Host Disease (cGVHD) |
|
E.1.1.1 | Medical condition in easily understood language |
cGVHD is immune system attack on normal tissue following transplantation of cells from a donor |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10066261 |
E.1.2 | Term | Chronic graft versus host disease |
E.1.2 | System Organ Class | 10021428 - Immune system disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of ibrutinib in combination with prednisone (Arm A) versus placebo in combination with prednisone (Arm B) based on the response rate at 24 weeks as determined by NIH Consensus Development Project criteria in subjects with new onset moderate to severe cGVHD. |
|
E.2.2 | Secondary objectives of the trial |
To compare the two treatment arms in terms of the following: Efficacy - Proportion of subjects obtaining steroid dose level less than 0.15 mg/kg/d at 24 weeks - Withdrawal of all immunosuppressants (with the exception of ibrutinib/placebo) at 48 weeks - Overall survival (OS) - Response rate at 48 weeks Safety - Safety and tolerability - Differences in steroid-related morbidities (eg, hyperglycemia, hypertension) |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Prior to randomization, each potential subject must satisfy all of the following inclusion criteria.
Disease related 1. New onset moderate or severe cGVHD as defined by the NIH Consensus Development Project Criteria (2014). 2. History of an allogeneic hematopoietic cell transplant. 3. Need for systemic treatment with corticosteroids for cGVHD. 4. No previous systemic treatment for cGVHD (including extracorporeal photopheresis [ECP]). 5. Participants may be receiving other immunosuppressants for the prophylaxis or treatment of acute GVHD but the doses of these medications must have been stable for at least 2 weeks prior to Screening. Prednisone dose must also be at or below 0.5 mg/kg/d at the time of randomization unless started within the previous 7 days for cGVHD. 6. Participants may have received pre-transplant ibrutinib for other reasons besides cGVHD such as for the treatment of leukemia or lymphoma, but must not have received a BTK inhibitor since the time of transplant.
Demographic 7. Age ≥12 years old. 8. Karnofsky or Lansky (subjects <16 years) performance score ≥60.
Laboratory 9. Adequate hepatic and renal function defined as: - AST, ALT ≤3 x ULN (unless of non-hepatic origin). If AST/ALT increase is associated with cGVHD then ≤5 x ULN is acceptable - Total bilirubin ≤1.5 x ULN (unless of non-hepatic origin or due to Gilbert’s Syndrome) - Estimated Creatinine Clearance ≥30 mL/min (Cockcroft-Gault formula) 10. Adequate hematological function defined as: - Absolute neutrophil count ≥1.0 x 109/L and off growth factor support for 7 days - Platelets ≥30 x 109/L and no transfusion for 7 days 11. PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonist, then INR ≤3.0.
Ethical/Other 12. Male and female subjects of reproductive potential who agree to use both a highly effective methods of birth control (eg, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (eg, condoms, cervical ring, sponge, etc) during the period of therapy and for 90 days for both females and males after the last dose of study drug. |
|
E.4 | Principal exclusion criteria |
To be enrolled in the study, potential subjects must meet NONE of the following exclusion criteria:
Disease related 1. Received any previous systemic treatment for cGVHD (with the exception of systemic corticosteroids started for cGVHD within 7 days of randomization). 2. Inability to begin a prednisone dose ≥0.5 mg/kg/d for the treatment of cGVHD.
Concurrent conditions 3. Received any investigational agent ≤28 days before randomization. 4. Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization. 5. Any uncontrolled active systemic infection or active infection requiring systemic treatment that was ongoing ≤7 days before randomization. 6. Progressive underlying malignant disease or any post-transplant lymphoproliferative disease. 7. History of other malignancy (not including the underlying malignancy that was the indication for transplant), with the following exceptions: - Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to Screening and felt to be at low risk for recurrence by treating physician - Adequately treated nonmelanomatous skin cancer or lentigo maligna melanoma without current evidence of disease - Adequately treated cervical carcinoma in situ without current evidence of disease 8. Subject has a concurrent illness which in the opinion of the investigator may interfere with the treatment and evaluation of the subject. 9. Known bleeding disorders (eg, von Willebrand’s disease or hemophilia). 10. History of stroke or intracranial hemorrhage within 6 months prior to randomization. 11. Known history of human immunodeficiency virus (HIV). 12. Subject with chronic liver disease with hepatic impairment per Child-Pugh classification Class B or C (Appendix E). 13. Active hepatitis C virus (HCV) or hepatitis B virus (HBV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen or hepatitis C antibody must have a negative polymerase chain reaction (PCR) result before randomization. Those who are PCR positive will be excluded. 14. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug. 15. Major surgery within 4 weeks of first dose of study drug. 16. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator’s opinion, could compromise the subject’s safety or put the study outcomes at undue risk. 17. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction. 18. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor (see Appendix D) with the exception of strong CYP3A inhibitors used for anti-fungal prophylaxis (eg, posaconazole). 19. Female subject who is pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 3 months of last dose study drug. Male subject who plans to father a child while enrolled in this study or within 3 months after the last dose of study drug. 20. Unwilling or unable to participate in all required study evaluations and procedures. 21. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the response rate at 24 weeks. Response will be defined by the NIH Consensus Development Project Criteria (2014) and must occur: - In the absence of new therapy for cGVHD In the absence of relapse or return of the underlying disease that was the indication for transplant (or post transplant lymphoproliferative disease [PTLD]), or death |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints will assess for additional clinical benefits including corticosteroid dose reduction, withdrawal of all immunosuppressants, and overall survival (OS). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Timepoints for the secondary end points are detailed in the 'Schedule of assessments' in Appendix A of the protocol |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 21 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Austria |
Canada |
China |
Croatia |
France |
Germany |
Hungary |
Italy |
Korea, Republic of |
Singapore |
Spain |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 15 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 15 |